PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome

Genes Chromosomes and Cancer

Volumn 52, Issue 3, 2013, Pages 265-273

  Toma, Marieta I ^a   Wuttig, Daniela ^a   Kaiser, Sandy ^a   Herr, Alexander ^b   Weber, Thomas ^a   Zastrow, Stefan ^a   Koch, Rainer ^c   Meinhardt, Matthias ^a   Baretton, Gustavo B ^a   Wirth, Manfred P ^a   Fuessel, Susanne ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Biotype Diagnostic GmbH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PARKINSON PROTEIN 2; PARKINSON PROTEIN 2 COREGULATED; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MALE; NEPHRECTOMY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; TISSUE MICROARRAY;

ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR CHAPERONES; NEOPLASM STAGING; RNA, MESSENGER; UBIQUITIN-PROTEIN LIGASES;

EID: 84872401497     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22026     Document Type: Article

References (35)

1. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L, Lahortiga I, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prosper F. 2006. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 118: 1945-1953.
2. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'Andrilli G, Scambia G, Picchio MC, Alder H, Godwin AK, Croce CM. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 100: 5956-5961.
3. Deng H, Le WD, Xie WJ, Pan TH, Zhang X, Jankovic J. 2005. Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. Neurosci Lett 382: 297-299.
4. Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI. 2003. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 38: 40-52.
5. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. 2006. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5: 2592-2601.
6. Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. 2010. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: A high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) 3: 1176-1186.
7. Gunawan B, Huber W, Holtrup M, von Heydebreck A, Efferth T, Poustka A, Ringert RH, Jakse G, Fuzesi L. 2001. Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: Gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res 61: 7731-7738.
8. Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O, Schwinger E, Vieregge P, Lang AE, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C. 2001. The importance of gene dosage studies: Mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet 10: 1649-1656.
9. Hedrich K, Eskelson C, Wilmot B, Marder K, Harris J, Garrels J, Meija-Santana H, Vieregge P, Jacobs H, Bressman SB, Lang AE, Kann M, Abbruzzese G, Martinelli P, Schwinger E, Ozelius LJ, Pramstaller PP, Klein C, Kramer P. 2004. Distribution, type, and origin of Parkin mutations: Review and case studies. Mov Disord 19: 1146-1157.
10. Ichimura K, Mungall AJ, Fiegler H, Pearson DM, Dunham I, Carter NP, Collins VP. 2006. Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH. Oncogene 25: 1261-1271.
11. Ikeda T. 2008. Parkin-co-regulated gene (PACRG) product interacts with tubulin and microtubules. FEBS Lett 582: 1413-1418.
12. Imai Y, Soda M, Murakami T, Shoji M, Abe K, Takahashi R. 2003. A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J Biol Chem 278: 51901-51910.
13. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. 2003. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
14. Junker K, Weirich G, Amin MB, Moravek P, Hindermann W, Schubert J. 2003. Genetic subtyping of renal cell carcinoma by comparative genomic hybridization. Recent Results Cancer Res 162: 169-175.
15. Lesage S, Magali P, Lohmann E, Lacomblez L, Teive H, Janin S, Cousin PY, Durr A, Brice A. 2007. Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism. Hum Mutat 28: 27-32.
16. Letessier A, Garrido-Urbani S, Ginestier C, Fournier G, Esterni B, Monville F, Adelaide J, Geneix J, Xerri L, Dubreuil P, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Lopez M, Chaffanet M. 2007. Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 26: 298-307.
17. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
18. McAvoy S, Ganapathiraju SC, Ducharme-Smith AL, Pritchett JR, Kosari F, Perez DS, Zhu Y, James CD, Smith DI. 2007. Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res 118: 260-269.
19. Moore DJ, West AB, Dikeman DA, Dawson VL, Dawson TM. 2008. Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem 105: 1806-1819.
20. Mulholland PJ, Fiegler H, Mazzanti C, Gorman P, Sasieni P, Adams J, Jones TA, Babbage JW, Vatcheva R, Ichimura K, Poullikas C, Collins VP, Carter NP, Tomlinson IP, Sheer D. 2006. Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle 5: 783-791.
21. Nguyen DX, Massague J. 2007. Genetic determinants of cancer metastasis. Nat Rev Genet 8: 341-352.
22. Parmar MKB, Machin D. 1995. Survival Analysis. Chichester: Wiley.
23. Pintilie M. 2006. Competing risks: A practical perspective. Chichester: Wiley.
24. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ. 2010. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA 107: 15145-15150.
25. Ren Y, Zhao J, Feng J. 2003. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 23: 3316-3324.
26. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305.
27. Taylor JM, Song YJ, Huang Y, Farrer MJ, Delatycki MB, Halliday GM, Lockhart PJ. 2007. Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases. Neurobiol Dis 27: 238-247.
28. Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, Fuessel S, Wuttig D, Wirth MP, Baretton GB. 2008. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 10: 634-642.
29. van Spronsen DJ, Mulders PF, De Mulder PH. 2005. Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol 55: 177-191.
30. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. 2010. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42: 77-82.
31. Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N, Schule B, Klein C, Shridhar V, Roberts LR, Smith DI. 2004. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40: 85-96.
32. West AB, Lockhart PJ, O'Farell C, Farrer MJ. 2003. Identification of a novel gene linked to parkin via a bi-directional promoter. J Mol Biol 326: 11-19.
33. West AB, Kapatos G, O'Farrell C, Gonzalez-de-Chavez F, Chiu K, Farrer MJ, Maidment NT. 2004. N-myc regulates parkin expression. J Biol Chem 279: 28896-28902.
34. Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Presti JC Jr, Kovacs G, Waldman FM. 2002. Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res 62: 957-960.
35. Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M, Ruckert C, Huynh T, Liu G, Kato M, Sanada M, Jauch A, Dugas M, Black KL, Koeffler HP. 2009. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res 7: 665-677.